Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Maria Lattanzi

Showing results (21-30 of 48) with videos related to

Pageof 5
Sort By:
Advances in Therapy|June 30, 2010
Comparison of half and full doses of an MF59-adjuvanted cell culture-derived A/H1N1v vaccine in Japanese childrenYuji Yasuda, Ryoya Komatsu, Kenji Matsushita, et al.
Neuroscience and Biobehavioral Reviews|September 8, 2019
Systematic review and multi-modal meta-analysis of magnetic resonance imaging findings in 22q11.2 deletion syndrome: Is more evidence needed?Cristina Scarpazza, Guido Maria Lattanzi, Mathilde Antoniades, et al.
The Pediatric Infectious Disease Journal|February 4, 2012
Immunogenicity, safety and reactogenicity of a mammalian cell-culture-derived influenza vaccine in healthy children and adolescents three to seventeen years of ageTimo Vesikari, Stan L Block, Fernando Guerra, et al.
Plos Neglected Tropical Diseases|May 27, 2025
Long-term persistence and boostability of immune responses following different rabies pre-exposure prophylaxis priming schedules of a purified chick embryo cell rabies vaccine administered alone or concomitantly with a Japanese encephalitis vaccineTomas Jelinek, Mirjam Schunk, Emil C Reisinger, et al.
Science Translational Medicine|June 3, 2011
MF59 adjuvant enhances diversity and affinity of antibody-mediated immune response to pandemic influenza vaccinesSurender Khurana, Nitin Verma, Jonathan W Yewdell, et al.
Human Vaccines & Immunotherapeutics|January 27, 2015
Immunogenicity and safety of cell-derived MF59®-adjuvanted A/H1N1 influenza vaccine for childrenMarkus Knuf, Geert Leroux-Roels, Hans Rümke, et al.
Msphere|April 8, 2025
Methods to evaluate the performance of a multicomponent meningococcal serogroup B vaccineRay Borrow, Laura Tomasi Cont, Daniela Toneatto, et al.
Drug Safety|November 12, 2022
Fully Liquid MenACWY-CRM Vaccine: Results from an Integrated Safety AnalysisPuneet Vir Singh, Paola Tiberi, Gabriele Filippo Di Domenico, et al.
Vaccine|April 5, 2012
Assessment of the immunogenicity and safety of varying doses of an MF59®-adjuvanted cell culture-derived A/H1N1 pandemic influenza vaccine in Japanese paediatric, adult and elderly subjectsHiroyuki Fukase, Hidetoshi Furuie, Yuji Yasuda, et al.
The Pediatric Infectious Disease Journal|July 1, 2014
Immunogenicity and tolerability of an MF59-adjuvanted, egg-derived, A/H1N1 pandemic influenza vaccine in children 6-35 months of ageMarkus Knuf, Geert Leroux-Roels, Hans C Rümke, et al.
Pageof 5

Showing results (21-30 of 48) with videos related to

Sort By:
Pageof 5
Advances in Therapy|June 30, 2010
Comparison of half and full doses of an MF59-adjuvanted cell culture-derived A/H1N1v vaccine in Japanese childrenYuji Yasuda, Ryoya Komatsu, Kenji Matsushita, et al.
Neuroscience and Biobehavioral Reviews|September 8, 2019
Systematic review and multi-modal meta-analysis of magnetic resonance imaging findings in 22q11.2 deletion syndrome: Is more evidence needed?Cristina Scarpazza, Guido Maria Lattanzi, Mathilde Antoniades, et al.
The Pediatric Infectious Disease Journal|February 4, 2012
Immunogenicity, safety and reactogenicity of a mammalian cell-culture-derived influenza vaccine in healthy children and adolescents three to seventeen years of ageTimo Vesikari, Stan L Block, Fernando Guerra, et al.
Plos Neglected Tropical Diseases|May 27, 2025
Long-term persistence and boostability of immune responses following different rabies pre-exposure prophylaxis priming schedules of a purified chick embryo cell rabies vaccine administered alone or concomitantly with a Japanese encephalitis vaccineTomas Jelinek, Mirjam Schunk, Emil C Reisinger, et al.
Science Translational Medicine|June 3, 2011
MF59 adjuvant enhances diversity and affinity of antibody-mediated immune response to pandemic influenza vaccinesSurender Khurana, Nitin Verma, Jonathan W Yewdell, et al.
Human Vaccines & Immunotherapeutics|January 27, 2015
Immunogenicity and safety of cell-derived MF59®-adjuvanted A/H1N1 influenza vaccine for childrenMarkus Knuf, Geert Leroux-Roels, Hans Rümke, et al.
Msphere|April 8, 2025
Methods to evaluate the performance of a multicomponent meningococcal serogroup B vaccineRay Borrow, Laura Tomasi Cont, Daniela Toneatto, et al.
Drug Safety|November 12, 2022
Fully Liquid MenACWY-CRM Vaccine: Results from an Integrated Safety AnalysisPuneet Vir Singh, Paola Tiberi, Gabriele Filippo Di Domenico, et al.
Vaccine|April 5, 2012
Assessment of the immunogenicity and safety of varying doses of an MF59®-adjuvanted cell culture-derived A/H1N1 pandemic influenza vaccine in Japanese paediatric, adult and elderly subjectsHiroyuki Fukase, Hidetoshi Furuie, Yuji Yasuda, et al.
The Pediatric Infectious Disease Journal|July 1, 2014
Immunogenicity and tolerability of an MF59-adjuvanted, egg-derived, A/H1N1 pandemic influenza vaccine in children 6-35 months of ageMarkus Knuf, Geert Leroux-Roels, Hans C Rümke, et al.
Pageof 5